Mount Sinai Innovation Partners
@MountSinai_IP
We facilitate the real-world application and commercialization of @MountSinaiNYC and @IcahnMountSinai discoveries and the development of research partnerships
ID:1479927060
http://www.ip.mountsinai.org 03-06-2013 15:18:00
2,8K Tweets
1,3K Followers
341 Following
Mark Lebwohl, MD, Dean for Clinical Therapeutics Icahn School of Medicine at Mount Sinai, shares an overview of his research investigating the use of bimekizumab treatment for hepatic adverse events among patients with moderate to severe psoriasis.
Learn more Healio: healio.com/news/dermatolo…
Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Icahn School of Medicine at Mount Sinai shares insight into his study regarding the use of pulsed field ablation catheters to isolate pulmonary veins in patients with paroxysmal atrial fibrillation.
Learn more: mims.com/specialty/topi…
We will be hosting our annual Demo Day of #ElementaLabs companies and other Mount Sinai companies and innovations on May 15! You'll learn about their healthcare products and have a chance to ask questions to company founders.
Sign up here: eventbrite.com/e/mount-sinai-…
Mark Lebwohl, MD, Dean for Clinical Therapeutics Icahn School of Medicine at Mount Sinai, shares an overview of his research investigating the use of bimekizumab treatment for hepatic adverse events among patients with moderate to severe psoriasis.
Learn more Healio: healio.com/news/dermatolo…
An international research team, including experts Icahn School of Medicine at Mount Sinai explain the ways that stress can result in major psychiatric conditions, such as depression.
Learn more: medicalxpress.com/news/2024-02-s…
Satish Nagula, MD, Icahn School of Medicine at Mount Sinai, discusses nine pieces of best practice advice shares best practice advice that addresses procedure optimization, evaluation of suspected premalignancy, and postprocedure follow-up evaluation.
Learn more Medscape: medscape.com/s/viewarticle/…
Mark Lebwohl, MD, Dean for Clinical Therapeutics Icahn School of Medicine at Mount Sinai, shares an overview of his research investigating the use of bimekizumab treatment for hepatic adverse events among patients with moderate to severe psoriasis.
Learn more: healio.com/news/dermatolo…
Sign up to receive innovation news, event updates, and information from Mount Sinai Innovation Partners. #IndustryInsights #TechTrends #ExclusiveEvents #NetworkingOpportunities
ow.ly/cVPZ50Rk27X
A myelofibrosis study showed that a combination of small-molecule therapy pelabresib with ruxolitinib (chemotherapy for myelofibrosis) led to better survival outcomes. John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai weighs in: curetoday.com/view/pelabresi… CURE Today Mount Sinai Department of Medicine
Congratulations to Click Therapeutics® on the U.S. FDA approval of Rejoyn™, a prescription digital therapeutic for major depressive disorder! Rejoyn™ incorporates brain training exercises, known as Emotional Faces Memory Task, which was developed @icahnmountsinai.
otsuka-us.com/news/rejoyn-fd…
An international research team, including experts at the Icahn School of Medicine at Mount Sinai explain the ways that stress can result in major psychiatric conditions, such as depression.
Learn more: medicalxpress.com/news/2024-02-s…
